Low immunogenicity of emicizumab in persons with haemophilia A-Reference-Cited by-同舟云学术

Low immunogenicity of emicizumab in persons with haemophilia A

Published:2021-09-04 Issue:6 Volume:27 Page:984-992
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Schmitt Christophe¹^ORCID,Emrich Thomas²,Chebon Sammy¹,Fernandez Elena¹,Petry Claire¹,Yoneyama Koichiro³,Kiialainen Anna¹,Howard Monet⁴,Niggli Markus¹,Paz‐Priel Ido⁵,Chang Tiffany⁵

Affiliation:

1. F. Hoffmann‐La Roche Ltd Basel Switzerland

2. Roche Diagnostics GmbH Penzberg Germany

3. Chugai Pharmaceutical Co. Ltd Tokyo Japan

4. Hoffmann‐La Roche Ltd Mississauga Canada

5. Genentech, Inc. South San Francisco California USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14398

Reference36 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. Factor VIII inhibitors in hemophilia A: rationale and latest evidence

3. WFH Guidelines for the Management of Hemophilia, 3rd edition

4. Practical aspects of extended half-life products for the treatment of haemophilia

5. The current status of prophylactic replacement therapy in children and adults with haemophilia

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

2. Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy;Thrombosis and Haemostasis;2024-08-12

3. Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents;Seminars in Thrombosis and Hemostasis;2024-06-12

4. Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies;mAbs;2024-06-06

5. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05